

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

ANTIGENICS INC /DE/
Form 8-K
May 27, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT FILED PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT
(Date of Earliest Event Reported):
May 21, 2004

ANTIGENICS INC.
(Exact Name of Registrant as Specified in its Charter)

DELAWARE (State or Other Jurisdiction of Incorporation or Organization)	000-29089 (Commission File Number)	06-1562417 (I.R.S. Employer Identification No.)
---	--	---

630 FIFTH AVENUE, SUITE 2100
NEW YORK, NEW YORK 10111
(Address of Principal Executive Offices and Zip Code)

(212) 994-8200
(Registrant's Telephone Number, Including Area Code)

ITEM 5. Other Events.

On May 21, 2004, Antigenics Inc. (the "Company") entered into a Right of First Refusal Agreement (the "Agreement") with Brad M. Kelley, an existing stockholder of the Company. A copy of the Agreement is filed herewith as Exhibit 4.1.

On May 26, 2004, the stockholders of the registrant approved Amendment No.1 to the Antigenics Inc. 1999 Equity Incentive Plan (the "Plan") to increase the number of shares of the registrant's common stock available under the Plan from 6 million to 10 million. A copy of the Plan, as amended, is filed herewith as Exhibit 10.1.

ITEM 7. Financial Statements, Pro Forma Financial Statements and Exhibits.

(c) Exhibits:

- 4.1 Right of First Refusal Agreement dated as of May 21, 2004, between Antigenics Inc. and Brad M. Kelley.
- 10.1 1999 Equity Incentive Plan, as amended.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

undersigned hereunto duly authorized.

ANTIGENICS INC.

Date: May 26, 2004

By: /s/ Garo H. Armen

Garo H. Armen
Chief Executive Officer

EXHIBIT INDEX

The following designated exhibits are filed herewith:

Exhibits:

Exhibit No. -----	Description -----
4.1	Right of First Refusal Agreement dated as of May 21, 2004, between Antigenics Inc. and Brad M. Kelley.
10.1	Amendment No. 2 to Antigenics Inc. 1999 Equity Incentive Plan.